期刊
DIAGNOSTICS
卷 11, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics11071188
关键词
platelets; breast cancer; biomarker; ADAM17; metastasis
资金
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy [EXC2180-39090067]
- Deutsche Forschungsgemeinschaft [374031971-TRR240, MA 8774/1-1, SA1360/7-3, 70112914]
- Institutional Strategy of the University of Tuebingen (Deutsche Forschungsgemeinschaft) [ZUK 63]
- Mainz Research School of Translational Biomedicine (TransMed) of the University of Mainz
- Wilhelm Sander-Stiftung [2007.115.3]
- University of Tuebingen
The study found that platelet-derived ADAM17 (pADAM17) in breast cancer patients is regulated upon platelet activation, unlike in healthy individuals. The downregulation of pADAM17 on platelets of cancer patients was correlated with clinical parameters related to tumor progression.
Tumor progression and metastasis are critically dependent on the tumor microenvironment. A disintegrin and metalloproteinase 17 (ADAM17) is associated with shedding of several substrates involved in tumor progression and known to be expressed by platelets of healthy donors and patients with solid tumors. Here, we report that platelet-derived ADAM17 (pADAM17) is regulated upon platelet activation of breast cancer patients, but not of healthy individuals. The observed downregulation of pADAM17 on platelets of cancer patients correlated with clinical parameters related to tumor progression including tumor stage and the occurrence of metastasis. Our data identify an association between platelet activation, modulation of platelet-derived ADAM17, and metastasis. In conclusion, we demonstrate that further development of pADAM17 as a liquid biomarker is warranted for monitoring disease progression in breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据